Lonza | chemanager-online.com - Chemistry and Life Science

Jul. 15, 2019
News & Opinions
Lonza Completes Tampa Expansion
Swiss fine chemicals producer and drug developer Lonza has completed a $15 million multi-phase expansion at its site in Tampa, Florida, USA, adding solid oral dose development and manufacturing capabilities. ...
Jul. 02, 2019
News & Opinions
Lonza to Acquire Swiss Facility from Novartis
Swiss fine chemicals producer and drug developer Lonza has signed a binding agreement to acquire a sterile drug product fill & finish plant from Novartis, the first such facility in its production network. In future, the company will ...
Jun. 04, 2019
News & Opinions
Lonza Splits Specialty Ingredients, Plans Job Cuts
Swiss fine chemicals company Lonza is carving out its specialty ingredients (LSI) segment under independent management, giving it increased control over operations and costs. LSI will, however, remain fully owned by Lonza. ...
Apr. 05, 2019
News & Opinions
Lonza and Chr Hansen in Biotherapeutics JV
Swiss fine chemicals producer Lonza and Danish biosciences company Chr. Hansen are forming a 50:50 joint venture to develop and manufacture live biotherapeutic products (LBPs) for pharma and biotech customers. ...
Jan. 31, 2019
News & Opinions
Funk to Follow Ridinger as Lonza CEO
Richard Ridinger, CEO of Basel, Switzerland-based fine chemicals producer Lonza since April 2012, will retire at the end of February and be succeeded on Mar. 1 by Marc Funk, current chief operating officer of the company’s Pharma ...
Dec. 12, 2018
News & Opinions
Lonza and GE Healthcare in China Biopharma Pact
Swiss-based Lonza is working with GE Healthcare, a General Electric subsidiary, to establish a biologics facility in Guangzhou, China. The deal will give Lonza a strategic base in China to respond to the country’s growing demand for ...
Nov. 20, 2018
News & Opinions
Sartorius Stedim and Lonza Modify Supply Pact
Biopharmaceutical supplier Sartorius Stedim Biotech and fine chemicals producer Lonza are modifying their 2012 agreement for supply of cell culture media, which gave SSB exclusive sales and marketing rights for certain media and buffers ...
Nov. 02, 2018
News & Opinions
DCAT Announces New Board of Directors
Paolo Magri, senior vice president, business development at Advitech, has been elected president of the Drug, Chemical & Associated Technologies Association (DCAT). Also elected to serve as officers of DCAT are: Stephan Kutzer, ...
Nov. 02, 2018
News & Opinions
Lonza to Sell Water Care to Platinum Equity
Lonza has agreed to sell its Water Care business to US investment group Platinum Equity for $630 million, while still discussing the inclusion of the company’s business in France. The deal is expected to close in the first ...
Oct. 04, 2018
News & Opinions
Lonza and Clovis Open New Monoplant for Ovarian Cancer Drug
Lonza and Clovis Oncology have opened a new, dedicated production train for Rubraca (rucaparib), at Lonza’s Visp site in Switzerland. Rubraca is Clovis’ US- and EU-approved drug for several ovarian cancer indications. Clovis ...

12 3 4 5 6 7 8…

Register now!

The latest information directly via newsletter.

GIT Verlag